US Patent

US12465608 — Osimertinib for use in the treatment of non-small cell lung cancer

Method of Use · Assigned to AstraZeneca AB · Expires 2042-11-26 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of osimertinib mesylate in combination with pemetrexed and platinum chemotherapy for treating non-small cell lung cancer.

USPTO Abstract

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naÃ¯ve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.

Drugs covered by this patent

osimertinib-mesylate (OSIMERTINIB MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3823`	—	osimertinib-mesylate
`U-3823`	—	osimertinib-mesylate

Patent Metadata

Patent number: US12465608
Jurisdiction: US
Classification: Method of Use
Expires: 2042-11-26
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.